TRA-8

TRA-8 is a **monoclonal antibody** that targets **tumor necrosis factor-related apoptosis-inducing ligand receptor 2** (TRAIL-R2, also known as DR5 or TNFRSF10B). It acts as an **agonist**, selectively binding to DR5 and inducing apoptosis in cancer cells expressing this receptor. The drug has been investigated primarily for its antitumor effects in various preclinical cancer models. TRA-8 was originally developed by researchers at the University of Alabama at Birmingham. Clinical and preclinical development has focused on solid tumors, particularly breast cancer, pancreatic cancer, and other malignancies where DR5 is expressed.